Vulnerabilities

Search by TI id or any alias (CVE, GHSA), vendor, product or CWE.

Filters

Reset all

Threatist priority CRITICAL 0 HIGH 0 MEDIUM 1 LOW 0

Signals Exploited in the wild (KEV) 0 Patch available 0 No fix listed 1 Has CVE 1

Fix status Fixed 0 Partial 0 Will not fix 0 Deferred 0 No fix listed 1

Impact type Code execution 0 Privilege escalation 0 Security bypass 1 Information disclosure 0 Tampering 0 Denial of service 0 Spoofing 0 Cross-site scripting 0 SQL injection 0

Attack vector Network 1 Adjacent network 0 Local 0 Physical 0

Requirements No authentication 0 No user interaction 1

Product

Products as named in CPE, with their records.

Published Last 7 days Last 30 days Last 12 months Any time

Weakness (CWE) CWE-264 1

2 selected

1 record

Sort

Vendor: Pfizer × Component: Symbiq Infusion System Firmware × Clear all filters

TI-2015-03351 CVE-2015-3965 · GHSA-fw6x-q668-xp72

Access control flaw in Hospira Symbiq Infusion System

Priority MEDIUM 43

Hospira Symbiq Infusion System 3.13 and earlier allows remote authenticated users to trigger "unanticipated operations" by leveraging "elevated privileges" for an unspecified call to an incorrectly exposed function.

CVSS 3.0HIGH 8.8· Network · Low privileges · No interaction · EPSS 0.02882 · Published 2019-03-23 · No fix listed CWE-264

THREATIST.IO

Vulnerability intelligence for security teams and AI agents.

Vulnerabilities Vendors Exploited (KEV) API & MCP Newsletter Privacy policy Terms of use

Newsletter Vulnerability intelligence in your inbox Subscribe

© 2026 Threatist.io · X (@threatist)Data: CVE Program, NVD, CISA KEV, FIRST EPSS, GitHub Advisory Database and Red Hat security data (both CC BY 4.0), Microsoft Security Response Center. This product uses the NVD API but is not endorsed or certified by the NVD. Sources and licences

We would like to use Google Analytics cookies to see how the site is used. They are set only if you accept. Privacy policy